___

• 1. Anderson DB, Zanella CA, Henley JM, Cimarotsi H. Sumoylation: Implications for Neurode-generative Diseases. Adv Exp Med Biol 2017; 963: 261-281. 2. Dorval V, Fraser PE. SUMO on the road to neurodegeneration. Biochim Biophys Acta 2007;1773: 694-706. 3. Li M, Guo D, Isales CM., Eizirik DL, Atkinson M, She JX, Wang CY. Sumo wrestling with type 1 diabetes. J Mol Med 2005; 83: 504- 513. 4. Wang CY, SHE JX. SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes Metab Res Rev 2008; 24: 93–102. 5. Bohren KM, nadkarni V, Song JH, Gabbay KH,Owerbach, D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004; 279: 27233–27238. 6. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DP, Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 15: 6455-6461. 7. Tatham MH, Jaffray E, Vaughan OA, Desterro JMP, Botting CH, Naismith JH, Hay RT. Polymeric Chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/ SAE2 and Ubc9. J Bio Chem 2001; 276(38): 35368-35374. 8. Wilkinson KA, Henley JM. Mechanisms, regulation and consequences of protein SUMOylation Biochem J 2012; 428(2): 133-145. 9. Martin S, Wilkinson KA, Nishimune A, Henly JM. Emergng exracellular roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci 2007; 8(12): 948- 959. 10. Song J, Durrin LK, Wilkinson TA, Krontiris TG, Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci 2004; 101: 14373-14378 11. Slow EF, Graham RF, Osmand AP ,Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR, Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005; 102: 11402–11407. 12. Krumova P, Weishaupt JH. Sumoylation in neurodegenerative diseases. Cell Mol Life Sci 2013; 70: 2123-2138. 13. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronaldysfunction in a polyglutamine disease model occurs in the absence ofubiquitin– proteasome system impairment and inversely correlates withthe degree of nuclear inclusion formation. Hum Mol Genet 2005; 14: 679-691. 14. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu Y-Z, Cattaneo E, Pandolfi P,Thompson LM, Marsh JL. SUMO modification of Huntingtin andHuntington’s disease pathology. Science 2004; 304: 100-104. 15. Subramaniam S, Sixt KM, Barrow R, Snyder SH. Rhes, a striatal specific protein, mediates mutant-huntingtincytotoxicity. Science 2009; 324: 1327-1330. 16. Terashima T, Kawai H, Fujitani M, Maeda K, Yasuda H. SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport 2002; 13:2359-2364. 17. Neumann M, Müller V, Görner K, Kretzschmar HA, Haass C, Kahle PJ. Pathological properties of the Parkinson’s disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol 2004; 107: 489-496. 18. Michels G, Hoppe UC. Rapid actions of and-rogens. Front Neuroendocrinol 2008; 29: 182-198. 19. Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM. Geneticmodulation of polyglutamine toxicity by protein conjugation pathways inDrosophila. Hum Mol Genet 2002; 11: 2895-2904. 20. Mukherjee S, Thomas M, Dadgar N, Lieberman AP,Iiguez-Lluh JA. Small ubiquitin-like modifier(SUMO) modification of the androgen receptor attenuatespolyglutamine-mediated aggregation. J BiolChem 2009; 284: 21296- 21306. 21. Poukka H, Karvonen U, Janne OA, Palvimo JJ. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci USA 2000; 97:14145-14150. 22. Chua JP, Reddy SL, Yu Z, Giorgetti E, Montie HL, Mukherjee S, Higgins J, McEachin RC, Robins DM,Merry DE, Iñiguez-Lluhí JA, Lieberman AP. Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest 2015; 2:831-845. 23. Ueda H, Goto J, Hashida H, Lin X, Oyanagi K, Kawano H, Zoghbi HY, Kanazawa I, Okazawa H. Enhanced SUMOylation in polyglutamine diseases. Biochem Biophys Res Commun 2002; 293: 307-313. 24. Ryu J, Cho S, Park BC, Lee Dh. Oxidative stressenhanced SUMOylation and aggregation of ataxin-1: implication of JNK pathway. Biochem Biophys Res Commun 2010; 393: 280-285. 25. Janer A, Werner A, Takahashi-Fujigasaki J, Daret A, Fujigasaki H, Takada K, Duyckaerts C, Brice A, Dejean A, Sittler A. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. Hum Mol Genet 2010; 19:181-195. 26. Lieberman AP, Robitaille Y, Trojanowski JQ, Dickson DW, Fischbeck KH. Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet 2010; 351:884 27. McFadden K, Hamilton RL, Insalaco SJ, Lavine L, Al-Mateen M, Wang G, Wiley CA. Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child. J Neuropathol Exp Neurol 2005; 64:545–552 28. Takahashi-Fujigasaki J, Arai K, Funata N, Fujigasaki H. SUMOylation substrates in neuronal intranuclear inclusion disease. Neuropathol Appl Neurobiol 2006; 32:92–100 29. Sone J, Tanaka F, Koike H, Inukai A, Katsuno M, Yoshida M, Watanabe H, Sobue G. Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease. Neurology 2011; 76:1372–1376 30. Zhao X, Sternsdorf T, Bolger TA, Evans RM, Yao TP. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 2005; 25:8456–8464 31. Eckermann K. SUMO and Parkinson’s disease. Neuromolecular Med. 2013; 15(4):737-59. doi: 10.1007/s12017-013-8259-5 32. Guerra de Souza AC, Prediger RD, Cimarosti H. SUMO-regulated mitochondrial function in Parkinson’s disease. Journal of Neurochemistry 2016;137:673-686 33. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 2005;123:383–396 34. Kunadt M, Eckermann K, Stuendl A, Gong J, Russo B, Strauss K, Rai S, Kügler S, Lockhart LF, Schwalbe M, Krumova P, Oliveira LMA, Bahr M, Mobius W, Levin J, Giese A, Kruse N, Mollenhauer B, Friedlander RG, Ludolph AC, Freischmidt A, Feiler MS, Danzer KM, Zweckstetter M, Jovin TM, Simons M, Weishaupt JH, Schneider A. Extracellular vesicle sorting of α-synuclein is regulated by SUMOylation. Acta Neuropathol 2015; 129: 695-713. 35. Krumova P, Weishaupt JH. Sumoylation in neurodegenerative diseases. Cell Mol Life Sci. 2013 Jun;70(12):2123-38. doi: 10.1007/ s00018-012-1158-3. Epub 2012 Sep 25. 36. Hoppe JB, Salbego CG, Cimarosti H. SUMOylation: Novel Neuroprotective Approach for Alzheimer’s Disease? Aging Dis. 2015; 1; 6(5): 322-30. 37. Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P. SUMO and Alzheimer’s disease. Neuromolecular Med. 2013; 15(4): 720-736. 38. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A, Jehu L, Segurado R, Stone D, Schadt E, Karnoub M, Nowotny P, Tacey K, Catanese J, Sninsky J, Brayne C, Rubinsztein D, Gill M, Lawlor B, Lovestone S, Holmans P, O’Donovan M, Morris JC, Thal L, Goate A, Owen MJ, Williams J. Evidence for novel susceptibility genes for late-onset Alzheimer’s disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007; 16(8): 865-873. 39. Weeraratna AT, Kalehua A, Deleon I, Bertak D, Maher G, Wade MS, Lustig A, Becker KG, Wood W, Walker DG, Beach TG, Taub DD. Alterations in immunological and neurological gene expression patterns in Alzheimer’s disease tissues. Exp Cell Res 2007; 1; 313(3):450-461. 40. Li Y, Wang H, Wang S, Quon D, Liu YW, Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc Natl Acad Sci USA. 2003; 7; 100(1): 259-64. 41. Martins WC, Tasca CI, Cimarosti H.Battling Alzheimer’s Disease: Targeting SUMOylation- Mediated Pathways. Neurochem Res. 2016; 41(3): 568-578.